GEM 21S Equimatrix Heli Products Mucograft References Download Center Video Education Center Lecture Materials
Professionals Patients Contact Us About Us
PRODUCTS
GEM 21S®
Optimatrix®
Equimatrix®
Heli Products
Purchase
NEWS
EVENTS
RESOURCES
CONTACT US
PLACE AN ORDER
REQUEST PRODUCT INFORMATION
LOGIN SITE MAP

HeliPLUG®, HeliTAPE® and HeliCOTE® are absorbable collagen wound dressing products intended to assist in the wound healing process.  HeliPLUG®, HeliTAPE® and HeliCOTE®:

  • are pliable, highly absorbent and very porous
  • provide a three-dimensional matrix for additional strengthening of the blood clot
  • are reabsorbed within 10-14 days after placement1
  • are produced using one of the purest sources of bovine collagen commercially available
  • easy to apply

 

HeliPLUG®

HeliPLUG® aids in the closure of extraction sites, controls bleeding in extraction sockets and biopsy sites.  HeliPLUG® Collagen Wound Dressings are approximately 3/8" x 3/4" (1 cm x 2 cm) and are packaged 10 units per box.

 

 

 

HeliTAPE®

HeliTAPE® protects the wound site, is used to repair the Schneiderian Membrane and controls bleeding due the hemostatic nature of collagen.  HeliTAPE® Collagen Wound Dressings are approximately 1" x 3" (2.5 cm x 7.5 cm) and are packaged 10 units per box.

 

 

HeliCOTE®

HeliCOTE® is indicated for use in palatal donor sites and to control bleeding.  HeliCOTE® Collagen Wound Dressings are approximately 3/4" x 1.5" (1.9 cm x 3.8 cm) and are packaged 10 units per box.

 

 

 

 

To view the Heli Product Package Insert, click here.
______________________
1Based on animal data.

 

 

 

 

SEARCH:
Osteohealth Company   |   Contact Us   |   © 2014 Luitpold Pharmaceuticals, Inc. Company   |   Privacy Policy   |   Terms of Use
DAIICHI SANKYO NAMES NEW PRESIDENT OF US SUBSIDIARY LUITPOLD PHARMACEUTICALS, INC.

June 29, 2016 – Effective today, Ken Keller has been newly appointed as President and CEO of Luitpold Pharmaceuticals, in addition to his current position as President, Daiichi Sankyo Administrative and Commercial, Daiichi Sankyo, Inc.

With more than 25 years of experience in the pharmaceutical industry in commercial leadership and joint venture leadership, Mr. Keller will now oversee both the Daiichi Sankyo, Inc. Commercial organization and Luitpold Pharmaceuticals, Inc.

Mr. Keller joined Daiichi Sankyo, Inc. in 2014 and has also served on the Luitpold Board of Directors since 2015. He has successfully led the Daiichi Sankyo, Inc. US commercial organization as it begins its transformation to a specialty focused company.

“While Luitpold and Daiichi Sankyo US businesses serve different customers and markets, they each bring to the table important strengths and focus that are essential to the continued success and growth of the Daiichi Sankyo Group,” said Ken Keller. “I look forward to working with the Luitpold team and driving even further success in the future.”

Luitpold Pharmaceuticals, Inc. is a Daiichi Sankyo Group Company headquartered in Shirley, NY, and manufactures more than 80 pharmaceutical products.